The Experts below are selected from a list of 129 Experts worldwide ranked by ideXlab platform
Rachel Lubong Sabado - One of the best experts on this subject based on the ideXlab platform.
-
resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with high risk melanoma
Cancer immunology research, 2015Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod DarvishianAbstract:The TLR7/8 agonist, Resiquimod has been used as an immune Adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide with or without Resiquimod in high risk melanoma patients. In Part I of the study, patients received 100ug full length NY-ESO-1 protein emulsified in 1.25mL Montanide (day 1) followed by topical application of 1000mg of 0.2% Resiquimod gel on days 1 and 3 (Cohort 1) versus days 1, 3, and 5 (Cohort 2) of a 21 day cycle. In Part II, patients were randomized to receive 100ug NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel (Arm-A; N=8) or 1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using the dosing regimen established in Part I. The vaccine regimens were generally well-tolerated. NY-ESO-1 specific humoral responses were induced or boosted in all patients, many with high titers. In Part II, 16 of 20 patients in both arms had NY-ESO-1-specific CD4+ T cell responses. CD8+ T cell responses were only seen in 3 of 12 patients in Arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1-specific CD8+ responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical Resiquimod is safe and induces both antibody and CD4+ cell responses in the majority of patients; the small proportion of CD8+ cell responses suggests that the addition of topical Resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1 specific CD8+ cell responses.
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal for ImmunoTherapy of Cancer, 2013Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie HolmanAbstract:Phase I/II study of Resiquimod as an Immunologic Adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal of Clinical Oncology, 2012Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, J EscalonAbstract:2589 Background: The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine Adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in patients with surgically resected stage IIB-IV melanoma patients. Methods: This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. Part II of the study is blinded. Patients were randomized to receive 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical applicat...
Sacha Gnjatic - One of the best experts on this subject based on the ideXlab platform.
-
resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with high risk melanoma
Cancer immunology research, 2015Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod DarvishianAbstract:The TLR7/8 agonist, Resiquimod has been used as an immune Adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide with or without Resiquimod in high risk melanoma patients. In Part I of the study, patients received 100ug full length NY-ESO-1 protein emulsified in 1.25mL Montanide (day 1) followed by topical application of 1000mg of 0.2% Resiquimod gel on days 1 and 3 (Cohort 1) versus days 1, 3, and 5 (Cohort 2) of a 21 day cycle. In Part II, patients were randomized to receive 100ug NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel (Arm-A; N=8) or 1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using the dosing regimen established in Part I. The vaccine regimens were generally well-tolerated. NY-ESO-1 specific humoral responses were induced or boosted in all patients, many with high titers. In Part II, 16 of 20 patients in both arms had NY-ESO-1-specific CD4+ T cell responses. CD8+ T cell responses were only seen in 3 of 12 patients in Arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1-specific CD8+ responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical Resiquimod is safe and induces both antibody and CD4+ cell responses in the majority of patients; the small proportion of CD8+ cell responses suggests that the addition of topical Resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1 specific CD8+ cell responses.
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal for ImmunoTherapy of Cancer, 2013Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie HolmanAbstract:Phase I/II study of Resiquimod as an Immunologic Adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal of Clinical Oncology, 2012Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, J EscalonAbstract:2589 Background: The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine Adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in patients with surgically resected stage IIB-IV melanoma patients. Methods: This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. Part II of the study is blinded. Patients were randomized to receive 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical applicat...
Farbod Darvishian - One of the best experts on this subject based on the ideXlab platform.
-
resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with high risk melanoma
Cancer immunology research, 2015Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod DarvishianAbstract:The TLR7/8 agonist, Resiquimod has been used as an immune Adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide with or without Resiquimod in high risk melanoma patients. In Part I of the study, patients received 100ug full length NY-ESO-1 protein emulsified in 1.25mL Montanide (day 1) followed by topical application of 1000mg of 0.2% Resiquimod gel on days 1 and 3 (Cohort 1) versus days 1, 3, and 5 (Cohort 2) of a 21 day cycle. In Part II, patients were randomized to receive 100ug NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel (Arm-A; N=8) or 1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using the dosing regimen established in Part I. The vaccine regimens were generally well-tolerated. NY-ESO-1 specific humoral responses were induced or boosted in all patients, many with high titers. In Part II, 16 of 20 patients in both arms had NY-ESO-1-specific CD4+ T cell responses. CD8+ T cell responses were only seen in 3 of 12 patients in Arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1-specific CD8+ responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical Resiquimod is safe and induces both antibody and CD4+ cell responses in the majority of patients; the small proportion of CD8+ cell responses suggests that the addition of topical Resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1 specific CD8+ cell responses.
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal for ImmunoTherapy of Cancer, 2013Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie HolmanAbstract:Phase I/II study of Resiquimod as an Immunologic Adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal of Clinical Oncology, 2012Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, J EscalonAbstract:2589 Background: The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine Adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in patients with surgically resected stage IIB-IV melanoma patients. Methods: This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. Part II of the study is blinded. Patients were randomized to receive 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical applicat...
Rose Marie Holman - One of the best experts on this subject based on the ideXlab platform.
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal for ImmunoTherapy of Cancer, 2013Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie HolmanAbstract:Phase I/II study of Resiquimod as an Immunologic Adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal of Clinical Oncology, 2012Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, J EscalonAbstract:2589 Background: The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine Adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in patients with surgically resected stage IIB-IV melanoma patients. Methods: This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. Part II of the study is blinded. Patients were randomized to receive 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical applicat...
Isabelita Vengco - One of the best experts on this subject based on the ideXlab platform.
-
resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with high risk melanoma
Cancer immunology research, 2015Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod DarvishianAbstract:The TLR7/8 agonist, Resiquimod has been used as an immune Adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide with or without Resiquimod in high risk melanoma patients. In Part I of the study, patients received 100ug full length NY-ESO-1 protein emulsified in 1.25mL Montanide (day 1) followed by topical application of 1000mg of 0.2% Resiquimod gel on days 1 and 3 (Cohort 1) versus days 1, 3, and 5 (Cohort 2) of a 21 day cycle. In Part II, patients were randomized to receive 100ug NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel (Arm-A; N=8) or 1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using the dosing regimen established in Part I. The vaccine regimens were generally well-tolerated. NY-ESO-1 specific humoral responses were induced or boosted in all patients, many with high titers. In Part II, 16 of 20 patients in both arms had NY-ESO-1-specific CD4+ T cell responses. CD8+ T cell responses were only seen in 3 of 12 patients in Arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1-specific CD8+ responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical Resiquimod is safe and induces both antibody and CD4+ cell responses in the majority of patients; the small proportion of CD8+ cell responses suggests that the addition of topical Resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1 specific CD8+ cell responses.
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal for ImmunoTherapy of Cancer, 2013Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie HolmanAbstract:Phase I/II study of Resiquimod as an Immunologic Adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
-
phase i ii study of resiquimod as an Immunologic Adjuvant for ny eso 1 protein vaccination in patients with melanoma
Journal of Clinical Oncology, 2012Co-Authors: Rachel Lubong Sabado, Anna C Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, J EscalonAbstract:2589 Background: The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine Adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in patients with surgically resected stage IIB-IV melanoma patients. Methods: This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. Part II of the study is blinded. Patients were randomized to receive 100ug NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical applicat...
